AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Rev...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethaso...
BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral dise...
HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering personalized treatments powered by predictive co...
-Vertex Pharmaceuticals Incorporated and Zai Lab Limited announced an exclusive collaboration and license agreement for the development a...
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...
Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by found...
-Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma announced a strategic partnership to accelerate the development and commercializatio...
Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...
Zai Lab Limited announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. to use MediLi...
Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administrat...
Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, anno...
Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders, announced the c...
etherna immunotherapies NV (“etherna”), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announc...
© 2025 Biopharma Boardroom. All Rights Reserved.
